Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium

Last updated: February 4, 2025
Sponsor: Belgian Research on AIDS and HIV Consortium
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hiv Infections

Aids And Aids Related Infections

Hiv

Treatment

N/A

Clinical Study ID

NCT06424964
2024/1-12
  • Ages 18-99
  • All Genders

Study Summary

This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes.

Primary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for the treatment of HIV

Secondary outcomes

• Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • HIV-1 patients, aged 18 years and above, having received at least 1 dose of LAI CAB/RPV between September 1, 2021, and March 31, 2024.

Study Design

Total Participants: 600
Study Start date:
January 13, 2025
Estimated Completion Date:
July 31, 2025

Connect with a study center

  • Saint-Pierre University Hospital

    Brussels,
    Belgium

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.